Zynext Ventures, The Vc Arm Of Zydus Lifesciences, Announces Investment In Promaxo: Pioneering Point-of-care Medical Imaging And Interventions With Next Generation Mri Systems

Zynext Ventures has invested in Promaxo, a US-based company that develops portable low-field MRI systems and minimally invasive robotics. This technology aims to revolutionize patient care by enabling point-of-care imaging and intervention, with the potential to improve outcomes and broaden access to vital medical procedures. Promaxo’s innovative system has already received FDA clearance for prostate biopsy and treatment, and the company is working towards clearance for its own robot to enhance precision and predictability. Zydus Lifesciences, the parent company of Zynext Ventures, is committed to supporting innovations that address unmet medical needs.